论文部分内容阅读
Management of insulin resistance is vital since failure to properly address this pathophysiological condition leads to the onset of type Ⅱ diabetes.Thiazolidinedione (TZD) drugs which are currently used for the treatment of insulin resistance are potent peroxisome proliferator-activated receptor Y (PPARy) ligands.